Global Neuromodulation Market - 2024 -2031
Report Overview
Global Neuro Modulation Devices Market reached US$5.4 billion in 2022 and is expected to reach US$7.6 billion by 2030, growing with a CAGR of 3.6% during the forecast period 2024-2031, according to DataM Intelligence report.
The trend such as the increasing adoption of organic strategies such as acquisition by key market players to expand its product portfolio, is expected to dominate the Global Neuromodulation Devices Market.
Neuromodulation devices are approved in the United States for the treatment of movement disorders, epilepsy, pain, and depression, and are used off-label for other neurologic indications
Neurostimulation devices involve the application of electrodes to the brain, the spinal cord or peripheral nerves. These precisely placed leads connect via an extension cable to a pulse generator and power source, which generates the necessary electrical stimulation. A low-voltage electrical current passes from the generator to the nerve and can either inhibit pain signals or stimulate neural impulses where they were previously absent.
Furthermore, the global neuromodulation devices are driven by various factors, the rise in the prevalence of lifestyle diseases such as chronic pain and depression, increased investment by private players for research and development of neurological disorders, and the increasing number of neurological diseases are some of the factors driving the market.
Moreover, the adoption of technologically advanced devices, the surge in the geriatric population, and the rise in demand for non-invasive and minimally invasive surgery fueled the industry growth having key players like Medtronic Plc, Abbott Laboratories, Boston Scientific Corp, LivaNova Plc and others.
Market Dynamics
Rise in the Prevalence of Neurological Disorders
The rise in the prevalence of neurological disorders is one of the key factors that helps the market to grow during the forecast period. For instance, the rise in the Prevalence of Epilepsy according to the WHO updated factsheet 2023, Epilepsy affects around 50 million individuals worldwide, making it one of the most common neurological illnesses. Almost 80% of epileptics reside in low- and middle-income nations. It is believed that if epilepsy is correctly identified and treated, up to 70% of people can live seizure-free.
Epilepsy affects 5 million people globally, with high-income countries experiencing 49 per 100,000 cases, while low- and middle-income countries have a higher rate of 139 per 100,000. This is due to increased risks of endemic conditions, road traffic injuries, birth-related injuries, and variations in medical infrastructure. Nearly 80% of epilepsy patients live in low- and middle-income countries.
Rise in the Technological Advancements
Key players frequently spend on R&D to generate more novel and effective neuromodulation devices. New technical breakthroughs enable the creation of more accurate, less intrusive technologies that provide improved patient results.
For instance, in addition, in the last few years, there have been various developments in neuromodulation technology. Some examples of these developments are rechargeable batteries with wireless charging, improvements in programming, less invasive single-stage implantation in outpatient settings, and lower-cost new devices.
Over the past decade, software and hardware technologies have advanced significantly, leading to significant technological successes. Hardware improvements have fueled software implementation and algorithmic integration, while sophisticated software enables efficient big data aggregation and biomarker discovery. Patients' familiarity with existing technology will facilitate the integration of digital health with neuromodulation therapies. The building blocks for effective solutions are often used in alternative applications, such as smartphones and smart watches for healthcare add-ons.
Rise in the Product Launches by Key Players
A rise in the product launches by key players in the market will help the overall market to grow during the forecast period. For instance, in July 2022 Orchestra BackBeat CNT, a highly sophisticated cardiac neuromodulation therapy, was created by collaboration between BioMed and Medtronic. It is combined with several antihypertensive drugs and is designed in a way that it operates automatically without depending on patient compliance. Furthermore, it can be simply modified to work with pacemakers and other cardiac rhythm control devices utilizing standard implant and lead installation techniques.
Additionally, in January 2022 Medtronic received FDA approval for its Intellis and Vanta rechargeable neurostimulator devices for treating chronic pain in diabetic peripheral neuropathy (DPN). DPN is a progressive neurological disorder affecting 30% of diabetes patients, causing numbness, burning, and severe pain. Medications are often only partially effective and can cause serious side effects.
High Cost of Neuromodulation Procedures
The high cost of neuromodulation procedures and devices is a major factor restraining the growth of the global neuromodulation market, especially in developing countries with poor reimbursement policies. The average cost of a standard implantable pulse generator is -USD implantation procedures can cost as high as USD 25,000—35,000.
Spinal cord stimulator devices cost around USD 13,000—40,000. Owing to high costs and a poor reimbursement scenario, a very limited pool of patients in developing countries can afford neurological treatment. As a result, healthcare facilities are reluctant to invest in new or technologically advanced systems, thus limiting the growth of the neuromodulation market.
Segment Analysis
The global neuromodulation devices market is segmented based on type, application, biomaterial, end user and region.
The Invasive Neuromodulation Segment From The Type Segment Accounted For Approximately 41.7% of Neuro Modulation Devices Share
The invasive neuromodulation segment from the type segment accounted for 41.7% and it is expected to be dominated during the forecast period. SCS devices deliver electrical pulses to the spinal cord to relieve chronic pain. They are often used as a treatment for failed back surgery syndrome, injuries to the spinal cord, complex regional pain syndrome, neuropathic pain, and ischemia-related refractory pain. The main benefits of the therapy are the decreased need for pain medication and overall improvement in the quality of life.
For instance, on April 19 2023 the company announced U.S. Food and Drug Administration (FDA) approval for Prospera, a spinal cord stimulation (SCS) system. The system features RESONANCE, the first and only multiphase stimulation paradigm, paired with Embrace One™, a patient-centric care model that makes proactive care possible by offering automatic, objective, daily remote monitoring and ongoing management and support.
Furthermore, in August 2022 Abbott announced that the U.S. Food and Drug Administration (FDA) has approved its new Proclaim Plus spinal cord stimulation (SCS) system featuring FlexBurst360 therapy. The next generation of Abbott's proprietary BurstDR stimulation, FlexBurst360 therapy, offers pain coverage across up to six areas of the trunk and/or limbs and enables programming that can be adjusted as a person's therapeutic needs evolve.
Designed to fit within a person's life, the Proclaim Plus SCS system is recharge-free with a battery that can last up to 10 years.^ It can be used with Abbott's NeuroSphere Virtual Clinic connected care technology, which allows a person to both communicate with a physician through secure in-app video chat and remotely receive stimulation settings in real-time regardless of location.
Geographical Share
North America Accounted for Approximately 38.4% of the Market Share
North America is estimated to hold about 38.4 % of the total market share throughout the forecast period, owing to the presence of major market players and huge pharmaceutical and biopharmaceutical industries, launches by key players, coupled with the rising investments in the country for the adoption of advanced technologies, an increasing number of patients suffering from neurological disorders, which is increasing the need for the adoption of neuromodulation devices, increased competition among market players, and significant expenditure on research and development.
On March 24, 2022, Medtronic plc, a global leader in healthcare technology, announced the first patient implants in the TITAN 2 pivotal study that will evaluate the safety and efficacy of Medtronic's investigational implantable tibial neuromodulation (TNM) device in people with overactive bladder (OAB). The minimally invasive technology stimulates the posterior tibial nerve near the ankle, transmitting electrical impulses that regulate the neural activity of the bladder.
For instance, in December 2022, Abbott announced the U.S. Food and Drug Administration (FDA) approval of the company's Eterna spinal cord stimulation (SCS) system – the smallest implantable, rechargeable spinal cord stimulator currently available on the market for the treatment of chronic pain. Eterna SCS utilizes Abbott's proprietary low-dose BurstDR stimulation, the only SCS waveform technology with the highest level of clinical evidence (1A evidence), proven to reduce pain 23% more than traditional waveform technology approaches.
Competitive Landscape
The major global players in the market include Medtronic Plc, Abbott Laboratories, Boston Scientific Corp, LivaNova Plc , Integer Holdings Corporation, ElectroCore, Caputron, NeuroPce Inc, Nevro Corporation, BrainsWay and among others.
COVID-19 Impact Analysis
In the wake of the COVID-19 pandemic, the neurostimulation devices industry witnessed a major slump, due to the supply chain challenges and a limited workforce. Several non-emergency surgical procedures were also postponed during the initial months of the crisis.
Also, in the case of TMS, there was already enthusiastic interest in accelerated TMS protocols for depression before the emergence of COVID-19. During a pandemic, potential reductions in time to response, treatment time, and overall days of treatment with accelerated intermittent theta-burst stimulation (aiTBS), in comparison to standard TMS protocols, may have exciting implications for mitigating viral transmission risk as well as for increasing treatment accessibility.
By Type
Target Audience 2023
Global Neuro Modulation Devices Market reached US$5.4 billion in 2022 and is expected to reach US$7.6 billion by 2030, growing with a CAGR of 3.6% during the forecast period 2024-2031, according to DataM Intelligence report.
The trend such as the increasing adoption of organic strategies such as acquisition by key market players to expand its product portfolio, is expected to dominate the Global Neuromodulation Devices Market.
Neuromodulation devices are approved in the United States for the treatment of movement disorders, epilepsy, pain, and depression, and are used off-label for other neurologic indications
Neurostimulation devices involve the application of electrodes to the brain, the spinal cord or peripheral nerves. These precisely placed leads connect via an extension cable to a pulse generator and power source, which generates the necessary electrical stimulation. A low-voltage electrical current passes from the generator to the nerve and can either inhibit pain signals or stimulate neural impulses where they were previously absent.
Furthermore, the global neuromodulation devices are driven by various factors, the rise in the prevalence of lifestyle diseases such as chronic pain and depression, increased investment by private players for research and development of neurological disorders, and the increasing number of neurological diseases are some of the factors driving the market.
Moreover, the adoption of technologically advanced devices, the surge in the geriatric population, and the rise in demand for non-invasive and minimally invasive surgery fueled the industry growth having key players like Medtronic Plc, Abbott Laboratories, Boston Scientific Corp, LivaNova Plc and others.
Market Dynamics
Rise in the Prevalence of Neurological Disorders
The rise in the prevalence of neurological disorders is one of the key factors that helps the market to grow during the forecast period. For instance, the rise in the Prevalence of Epilepsy according to the WHO updated factsheet 2023, Epilepsy affects around 50 million individuals worldwide, making it one of the most common neurological illnesses. Almost 80% of epileptics reside in low- and middle-income nations. It is believed that if epilepsy is correctly identified and treated, up to 70% of people can live seizure-free.
Epilepsy affects 5 million people globally, with high-income countries experiencing 49 per 100,000 cases, while low- and middle-income countries have a higher rate of 139 per 100,000. This is due to increased risks of endemic conditions, road traffic injuries, birth-related injuries, and variations in medical infrastructure. Nearly 80% of epilepsy patients live in low- and middle-income countries.
Rise in the Technological Advancements
Key players frequently spend on R&D to generate more novel and effective neuromodulation devices. New technical breakthroughs enable the creation of more accurate, less intrusive technologies that provide improved patient results.
For instance, in addition, in the last few years, there have been various developments in neuromodulation technology. Some examples of these developments are rechargeable batteries with wireless charging, improvements in programming, less invasive single-stage implantation in outpatient settings, and lower-cost new devices.
Over the past decade, software and hardware technologies have advanced significantly, leading to significant technological successes. Hardware improvements have fueled software implementation and algorithmic integration, while sophisticated software enables efficient big data aggregation and biomarker discovery. Patients' familiarity with existing technology will facilitate the integration of digital health with neuromodulation therapies. The building blocks for effective solutions are often used in alternative applications, such as smartphones and smart watches for healthcare add-ons.
Rise in the Product Launches by Key Players
A rise in the product launches by key players in the market will help the overall market to grow during the forecast period. For instance, in July 2022 Orchestra BackBeat CNT, a highly sophisticated cardiac neuromodulation therapy, was created by collaboration between BioMed and Medtronic. It is combined with several antihypertensive drugs and is designed in a way that it operates automatically without depending on patient compliance. Furthermore, it can be simply modified to work with pacemakers and other cardiac rhythm control devices utilizing standard implant and lead installation techniques.
Additionally, in January 2022 Medtronic received FDA approval for its Intellis and Vanta rechargeable neurostimulator devices for treating chronic pain in diabetic peripheral neuropathy (DPN). DPN is a progressive neurological disorder affecting 30% of diabetes patients, causing numbness, burning, and severe pain. Medications are often only partially effective and can cause serious side effects.
High Cost of Neuromodulation Procedures
The high cost of neuromodulation procedures and devices is a major factor restraining the growth of the global neuromodulation market, especially in developing countries with poor reimbursement policies. The average cost of a standard implantable pulse generator is -USD implantation procedures can cost as high as USD 25,000—35,000.
Spinal cord stimulator devices cost around USD 13,000—40,000. Owing to high costs and a poor reimbursement scenario, a very limited pool of patients in developing countries can afford neurological treatment. As a result, healthcare facilities are reluctant to invest in new or technologically advanced systems, thus limiting the growth of the neuromodulation market.
Segment Analysis
The global neuromodulation devices market is segmented based on type, application, biomaterial, end user and region.
The Invasive Neuromodulation Segment From The Type Segment Accounted For Approximately 41.7% of Neuro Modulation Devices Share
The invasive neuromodulation segment from the type segment accounted for 41.7% and it is expected to be dominated during the forecast period. SCS devices deliver electrical pulses to the spinal cord to relieve chronic pain. They are often used as a treatment for failed back surgery syndrome, injuries to the spinal cord, complex regional pain syndrome, neuropathic pain, and ischemia-related refractory pain. The main benefits of the therapy are the decreased need for pain medication and overall improvement in the quality of life.
For instance, on April 19 2023 the company announced U.S. Food and Drug Administration (FDA) approval for Prospera, a spinal cord stimulation (SCS) system. The system features RESONANCE, the first and only multiphase stimulation paradigm, paired with Embrace One™, a patient-centric care model that makes proactive care possible by offering automatic, objective, daily remote monitoring and ongoing management and support.
Furthermore, in August 2022 Abbott announced that the U.S. Food and Drug Administration (FDA) has approved its new Proclaim Plus spinal cord stimulation (SCS) system featuring FlexBurst360 therapy. The next generation of Abbott's proprietary BurstDR stimulation, FlexBurst360 therapy, offers pain coverage across up to six areas of the trunk and/or limbs and enables programming that can be adjusted as a person's therapeutic needs evolve.
Designed to fit within a person's life, the Proclaim Plus SCS system is recharge-free with a battery that can last up to 10 years.^ It can be used with Abbott's NeuroSphere Virtual Clinic connected care technology, which allows a person to both communicate with a physician through secure in-app video chat and remotely receive stimulation settings in real-time regardless of location.
Geographical Share
North America Accounted for Approximately 38.4% of the Market Share
North America is estimated to hold about 38.4 % of the total market share throughout the forecast period, owing to the presence of major market players and huge pharmaceutical and biopharmaceutical industries, launches by key players, coupled with the rising investments in the country for the adoption of advanced technologies, an increasing number of patients suffering from neurological disorders, which is increasing the need for the adoption of neuromodulation devices, increased competition among market players, and significant expenditure on research and development.
On March 24, 2022, Medtronic plc, a global leader in healthcare technology, announced the first patient implants in the TITAN 2 pivotal study that will evaluate the safety and efficacy of Medtronic's investigational implantable tibial neuromodulation (TNM) device in people with overactive bladder (OAB). The minimally invasive technology stimulates the posterior tibial nerve near the ankle, transmitting electrical impulses that regulate the neural activity of the bladder.
For instance, in December 2022, Abbott announced the U.S. Food and Drug Administration (FDA) approval of the company's Eterna spinal cord stimulation (SCS) system – the smallest implantable, rechargeable spinal cord stimulator currently available on the market for the treatment of chronic pain. Eterna SCS utilizes Abbott's proprietary low-dose BurstDR stimulation, the only SCS waveform technology with the highest level of clinical evidence (1A evidence), proven to reduce pain 23% more than traditional waveform technology approaches.
Competitive Landscape
The major global players in the market include Medtronic Plc, Abbott Laboratories, Boston Scientific Corp, LivaNova Plc , Integer Holdings Corporation, ElectroCore, Caputron, NeuroPce Inc, Nevro Corporation, BrainsWay and among others.
COVID-19 Impact Analysis
In the wake of the COVID-19 pandemic, the neurostimulation devices industry witnessed a major slump, due to the supply chain challenges and a limited workforce. Several non-emergency surgical procedures were also postponed during the initial months of the crisis.
Also, in the case of TMS, there was already enthusiastic interest in accelerated TMS protocols for depression before the emergence of COVID-19. During a pandemic, potential reductions in time to response, treatment time, and overall days of treatment with accelerated intermittent theta-burst stimulation (aiTBS), in comparison to standard TMS protocols, may have exciting implications for mitigating viral transmission risk as well as for increasing treatment accessibility.
By Type
- Invasive Neuromodulation
- Spinal Cord Stimulation (SCS)
- Deep Brain Stimulation (DBS)
- Sacral Nerve Stimulation (SNS)
- Vagus Nerve Stimulation (VNS)
- Gastric Electric Stimulation (GES)
- Non-Invasive Neuromodulation
- Transcutaneous Electrical Nerve Stimulation (TENS)
- Transcranial Magnetic Stimulation (TMS)
- Respiratory Electrical Stimulation (RES)
- Parkinson’s Disease
- Migraine
- Epilepsy
- Pain Management
- Tremor
- Others
- Metallic Biomaterials
- Polymeric Biomaterials
- Ceramic Biomaterials
- Hospitals
- Ambulatory Surgical Centers
- Specialized Clinics
- Others
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific
- Middle East and Africa
- In November 2022, CVRx—the developer of the world’s first US Food and Drug Administration (FDA)-approved neuromodulation device to treat the symptoms of heart failure—has launched its new Barostim NEO2 implantable pulse generator (IPG). The second-generation device reduces the size of the IPG by 10% and extends battery life by 20%, reducing the frequency of device replacements for patients and their providers, a CVRx press release notes.
- In July 2022, Helius Medical Technologies, Inc. received the United States Food and Drug Administration for its PoNSTM which provides electrical pulses to the tongue for use along with physical therapy as a short-term treatment for mild to moderate walking (gait) problems in people.
- In July 2022, Abbott received the United States Food and Drug Administration (FDA) Breakthrough Device Designation to investigate the use of its deep brain stimulation (DBS) system in treatment-resistant depression (TRD).
- To visualize the global neuro modulation devices market segmentation based on type, application, biomaterials, end user and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of global neuro modulation devices market level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
Target Audience 2023
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Type
3.2. Snippet by Application
3.3. Snippet by Biomaterial
3.4. Snippet by End User
3.5. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in the Prevalence of Neurological Disorders
4.1.1.2. Rise in the Technological Advancements
4.1.1.3. Rise in the Product Launches by Key Players
4.1.2. Restraints
4.1.2.1. High Cost of Neuromodulation Procedures
4.1.3. Opportunity
4.1.3.1. Increasing Demand for Minimally Invasive Surgery in Developed Countries
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 ANALYSIS
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY TYPE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Invasive Neuromodulation*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Non-Invasive Neuromodulation
8. BY APPLICATION
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Parkinson’s Disease*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Migraine
8.4. Epilepsy
8.5. Pain Management
8.6. Tremor
8.7. Others
9. BY BIOMATERIAL
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Metallic Biomaterials *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Polymeric Biomaterials
9.4. Ceramic Biomaterials
10. BY END USER
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.1.2. Market Attractiveness Index, By End User
10.2. Hospitals*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Ambulatory Surgical Centers
10.4. Specialized Clinics
10.5. Others
11. BY REGION
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomaterial
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomaterial
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomaterial
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomaterial
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomaterial
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12. COMPETITIVE LANDSCAPE
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. COMPANY PROFILES
13.1. Medtronic Plc *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Abbott Laboratories
13.3. Boston Scientific Corp
13.4. LivaNova Plc
13.5. Integer Holdings Corporation
13.6. ElectroCore
13.7. Caputron
13.8. NeuroPce Inc
13.9. Nevro Corporation
13.10. BrainsWay (*LIST NOT EXHAUSTIVE)
14. APPENDIX
14.1. About Us and Services
14.2. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Type
3.2. Snippet by Application
3.3. Snippet by Biomaterial
3.4. Snippet by End User
3.5. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in the Prevalence of Neurological Disorders
4.1.1.2. Rise in the Technological Advancements
4.1.1.3. Rise in the Product Launches by Key Players
4.1.2. Restraints
4.1.2.1. High Cost of Neuromodulation Procedures
4.1.3. Opportunity
4.1.3.1. Increasing Demand for Minimally Invasive Surgery in Developed Countries
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 ANALYSIS
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. BY TYPE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Invasive Neuromodulation*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Non-Invasive Neuromodulation
8. BY APPLICATION
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Parkinson’s Disease*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Migraine
8.4. Epilepsy
8.5. Pain Management
8.6. Tremor
8.7. Others
9. BY BIOMATERIAL
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Metallic Biomaterials *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Polymeric Biomaterials
9.4. Ceramic Biomaterials
10. BY END USER
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.1.2. Market Attractiveness Index, By End User
10.2. Hospitals*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Ambulatory Surgical Centers
10.4. Specialized Clinics
10.5. Others
11. BY REGION
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomaterial
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomaterial
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomaterial
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomaterial
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Biomaterial
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12. COMPETITIVE LANDSCAPE
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. COMPANY PROFILES
13.1. Medtronic Plc *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Abbott Laboratories
13.3. Boston Scientific Corp
13.4. LivaNova Plc
13.5. Integer Holdings Corporation
13.6. ElectroCore
13.7. Caputron
13.8. NeuroPce Inc
13.9. Nevro Corporation
13.10. BrainsWay (*LIST NOT EXHAUSTIVE)
14. APPENDIX
14.1. About Us and Services
14.2. Contact Us
LIST OF TABLES
Table 1 Global Neuromodulation Devices Market Value, By Type, 2022, 2026 & 2030 (US$ Billion)
Table 2 Global Neuromodulation Devices Market Value, By Application, 2022, 2026 & 2030 (US$ Billion)
Table 3 Global Neuromodulation Devices Market Value, By Biomaterial, 2022, 2026 & 2030 (US$ Billion)
Table 4 Global Neuromodulation Devices Market Value, By End-User, 2022, 2026 & 2030 (US$ Billion)
Table 5 Global Neuromodulation Devices Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)
Table 6 Global Neuromodulation Devices Market Value, By Type, 2022, 2026 & 2030 (US$ Billion)
Table 7 Global Neuromodulation Devices Market Value, By Type, 2021-2030 (US$ Billion)
Table 8 Global Neuromodulation Devices Market Value, By Application, 2022, 2026 & 2030 (US$ Billion)
Table 9 Global Neuromodulation Devices Market Value, By Application, 2021-2030 (US$ Billion)
Table 10 Global Neuromodulation Devices Market Value, By Biomaterial, 2022, 2026 & 2030 (US$ Billion)
Table 11 Global Neuromodulation Devices Market Value, By Biomaterial, 2021-2030 (US$ Billion)
Table 12 Global Neuromodulation Devices Market Value, By End-User, 2022, 2026 & 2030 (US$ Billion)
Table 13 Global Neuromodulation Devices Market Value, By End-User, 2021-2030 (US$ Billion)
Table 14 Global Neuromodulation Devices Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)
Table 15 Global Neuromodulation Devices Market Value, By Region, 2021-2030 (US$ Billion)
Table 16 North America Neuromodulation Devices Market Value, By Type, 2021-2030 (US$ Billion)
Table 17 North America Neuromodulation Devices Market Value, By Application, 2021-2030 (US$ Billion)
Table 18 North America Neuromodulation Devices Market Value, By Biomaterial, 2021-2030 (US$ Billion)
Table 19 North America Neuromodulation Devices Market Value, By End-User, 2021-2030 (US$ Billion)
Table 20 North America Neuromodulation Devices Market Value, By Country, 2021-2030 (US$ Billion)
Table 21 South America Neuromodulation Devices Market Value, By Type, 2021-2030 (US$ Billion)
Table 22 South America Neuromodulation Devices Market Value, By Application, 2021-2030 (US$ Billion)
Table 23 South America Neuromodulation Devices Market Value, By Biomaterial, 2021-2030 (US$ Billion)
Table 24 South America Neuromodulation Devices Market Value, By End-User, 2021-2030 (US$ Billion)
Table 25 South America Neuromodulation Devices Market Value, By Country, 2021-2030 (US$ Billion)
Table 26 Europe Neuromodulation Devices Market Value, By Type, 2021-2030 (US$ Billion)
Table 27 Europe Neuromodulation Devices Market Value, By Application, 2021-2030 (US$ Billion)
Table 28 Europe Neuromodulation Devices Market Value, By Biomaterial, 2021-2030 (US$ Billion)
Table 29 Europe Neuromodulation Devices Market Value, By End-User, 2021-2030 (US$ Billion)
Table 30 Europe Neuromodulation Devices Market Value, By Country, 2021-2030 (US$ Billion)
Table 31 Asia-Pacific Neuromodulation Devices Market Value, By Type, 2021-2030 (US$ Billion)
Table 32 Asia-Pacific Neuromodulation Devices Market Value, By Application, 2021-2030 (US$ Billion)
Table 33 Asia-Pacific Neuromodulation Devices Market Value, By Biomaterial, 2021-2030 (US$ Billion)
Table 34 Asia-Pacific Neuromodulation Devices Market Value, By End-User, 2021-2030 (US$ Billion)
Table 35 Asia-Pacific Neuromodulation Devices Market Value, By Country, 2021-2030 (US$ Billion)
Table 36 Middle East & Africa Neuromodulation Devices Market Value, By Type, 2021-2030 (US$ Billion)
Table 37 Middle East & Africa Neuromodulation Devices Market Value, By Application, 2021-2030 (US$ Billion)
Table 38 Middle East & Africa Neuromodulation Devices Market Value, By Biomaterial, 2021-2030 (US$ Billion)
Table 39 Middle East & Africa Neuromodulation Devices Market Value, By End-User, 2021-2030 (US$ Billion)
Table 40 Medtronic Plc : Overview
Table 41 Medtronic Plc : Product Portfolio
Table 42 Medtronic Plc : Key Developments
Table 43 Abbott Laboratories : Overview
Table 44 Abbott Laboratories : Product Portfolio
Table 45 Abbott Laboratories : Key Developments
Table 46 Boston Scientific Corp : Overview
Table 47 Boston Scientific Corp : Product Portfolio
Table 48 Boston Scientific Corp : Key Developments
Table 49 LivaNova Plc : Overview
Table 50 LivaNova Plc : Product Portfolio
Table 51 LivaNova Plc : Key Developments
Table 52 Integer Holdings Corporation: Overview
Table 53 Integer Holdings Corporation: Product Portfolio
Table 54 Integer Holdings Corporation: Key Developments
Table 55 ElectroCore: Overview
Table 56 ElectroCore: Product Portfolio
Table 57 ElectroCore: Key Developments
Table 58 Caputron: Overview
Table 59 Caputron: Product Portfolio
Table 60 Caputron: Key Developments
Table 61 NeuroPce Inc: Overview
Table 62 NeuroPce Inc: Product Portfolio
Table 63 NeuroPce Inc: Key Developments
Table 64 Nevro Corporation: Overview
Table 65 Nevro Corporation: Product Portfolio
Table 66 Nevro Corporation: Key Developments
Table 67 BrainsWay: Overview
Table 68 BrainsWay: Product Portfolio
Table 69 BrainsWay: Key Developments
Table 1 Global Neuromodulation Devices Market Value, By Type, 2022, 2026 & 2030 (US$ Billion)
Table 2 Global Neuromodulation Devices Market Value, By Application, 2022, 2026 & 2030 (US$ Billion)
Table 3 Global Neuromodulation Devices Market Value, By Biomaterial, 2022, 2026 & 2030 (US$ Billion)
Table 4 Global Neuromodulation Devices Market Value, By End-User, 2022, 2026 & 2030 (US$ Billion)
Table 5 Global Neuromodulation Devices Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)
Table 6 Global Neuromodulation Devices Market Value, By Type, 2022, 2026 & 2030 (US$ Billion)
Table 7 Global Neuromodulation Devices Market Value, By Type, 2021-2030 (US$ Billion)
Table 8 Global Neuromodulation Devices Market Value, By Application, 2022, 2026 & 2030 (US$ Billion)
Table 9 Global Neuromodulation Devices Market Value, By Application, 2021-2030 (US$ Billion)
Table 10 Global Neuromodulation Devices Market Value, By Biomaterial, 2022, 2026 & 2030 (US$ Billion)
Table 11 Global Neuromodulation Devices Market Value, By Biomaterial, 2021-2030 (US$ Billion)
Table 12 Global Neuromodulation Devices Market Value, By End-User, 2022, 2026 & 2030 (US$ Billion)
Table 13 Global Neuromodulation Devices Market Value, By End-User, 2021-2030 (US$ Billion)
Table 14 Global Neuromodulation Devices Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)
Table 15 Global Neuromodulation Devices Market Value, By Region, 2021-2030 (US$ Billion)
Table 16 North America Neuromodulation Devices Market Value, By Type, 2021-2030 (US$ Billion)
Table 17 North America Neuromodulation Devices Market Value, By Application, 2021-2030 (US$ Billion)
Table 18 North America Neuromodulation Devices Market Value, By Biomaterial, 2021-2030 (US$ Billion)
Table 19 North America Neuromodulation Devices Market Value, By End-User, 2021-2030 (US$ Billion)
Table 20 North America Neuromodulation Devices Market Value, By Country, 2021-2030 (US$ Billion)
Table 21 South America Neuromodulation Devices Market Value, By Type, 2021-2030 (US$ Billion)
Table 22 South America Neuromodulation Devices Market Value, By Application, 2021-2030 (US$ Billion)
Table 23 South America Neuromodulation Devices Market Value, By Biomaterial, 2021-2030 (US$ Billion)
Table 24 South America Neuromodulation Devices Market Value, By End-User, 2021-2030 (US$ Billion)
Table 25 South America Neuromodulation Devices Market Value, By Country, 2021-2030 (US$ Billion)
Table 26 Europe Neuromodulation Devices Market Value, By Type, 2021-2030 (US$ Billion)
Table 27 Europe Neuromodulation Devices Market Value, By Application, 2021-2030 (US$ Billion)
Table 28 Europe Neuromodulation Devices Market Value, By Biomaterial, 2021-2030 (US$ Billion)
Table 29 Europe Neuromodulation Devices Market Value, By End-User, 2021-2030 (US$ Billion)
Table 30 Europe Neuromodulation Devices Market Value, By Country, 2021-2030 (US$ Billion)
Table 31 Asia-Pacific Neuromodulation Devices Market Value, By Type, 2021-2030 (US$ Billion)
Table 32 Asia-Pacific Neuromodulation Devices Market Value, By Application, 2021-2030 (US$ Billion)
Table 33 Asia-Pacific Neuromodulation Devices Market Value, By Biomaterial, 2021-2030 (US$ Billion)
Table 34 Asia-Pacific Neuromodulation Devices Market Value, By End-User, 2021-2030 (US$ Billion)
Table 35 Asia-Pacific Neuromodulation Devices Market Value, By Country, 2021-2030 (US$ Billion)
Table 36 Middle East & Africa Neuromodulation Devices Market Value, By Type, 2021-2030 (US$ Billion)
Table 37 Middle East & Africa Neuromodulation Devices Market Value, By Application, 2021-2030 (US$ Billion)
Table 38 Middle East & Africa Neuromodulation Devices Market Value, By Biomaterial, 2021-2030 (US$ Billion)
Table 39 Middle East & Africa Neuromodulation Devices Market Value, By End-User, 2021-2030 (US$ Billion)
Table 40 Medtronic Plc : Overview
Table 41 Medtronic Plc : Product Portfolio
Table 42 Medtronic Plc : Key Developments
Table 43 Abbott Laboratories : Overview
Table 44 Abbott Laboratories : Product Portfolio
Table 45 Abbott Laboratories : Key Developments
Table 46 Boston Scientific Corp : Overview
Table 47 Boston Scientific Corp : Product Portfolio
Table 48 Boston Scientific Corp : Key Developments
Table 49 LivaNova Plc : Overview
Table 50 LivaNova Plc : Product Portfolio
Table 51 LivaNova Plc : Key Developments
Table 52 Integer Holdings Corporation: Overview
Table 53 Integer Holdings Corporation: Product Portfolio
Table 54 Integer Holdings Corporation: Key Developments
Table 55 ElectroCore: Overview
Table 56 ElectroCore: Product Portfolio
Table 57 ElectroCore: Key Developments
Table 58 Caputron: Overview
Table 59 Caputron: Product Portfolio
Table 60 Caputron: Key Developments
Table 61 NeuroPce Inc: Overview
Table 62 NeuroPce Inc: Product Portfolio
Table 63 NeuroPce Inc: Key Developments
Table 64 Nevro Corporation: Overview
Table 65 Nevro Corporation: Product Portfolio
Table 66 Nevro Corporation: Key Developments
Table 67 BrainsWay: Overview
Table 68 BrainsWay: Product Portfolio
Table 69 BrainsWay: Key Developments
LIST OF FIGURES
Figure 1 Global Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 2 Global Neuromodulation Devices Market Share, By Type, 2022 & 2030 (%)
Figure 3 Global Neuromodulation Devices Market Share, By Application, 2022 & 2030 (%)
Figure 4 Global Neuromodulation Devices Market Share, By Biomaterial, 2022 & 2030 (%)
Figure 5 Global Neuromodulation Devices Market Share, By End-User, 2022 & 2030 (%)
Figure 6 Global Neuromodulation Devices Market Share, By Region, 2022 & 2030 (%)
Figure 7 Global Neuromodulation Devices Market Y-o-Y Growth, By Type, 2022-2030 (%)
Figure 8 Invasive Neuromodulation Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 9 Non Invasive Neuromodulation Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 10 Global Neuromodulation Devices Market Y-o-Y Growth, By Application, 2022-2030 (%)
Figure 11 Parkinson’s Disease Application in Global Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 12 Migraine Application in Global Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 13 Epilepsy Application in Global Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 14 Pain Management Application in Global Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 15 Tremor Application in Global Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 16 Depression Application in Global Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 17 Others Application in Global Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 18 Global Neuromodulation Devices Market Y-o-Y Growth, By Biomaterial, 2022-2030 (%)
Figure 19 Metallic Biomaterials Biomaterial in Global Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 20 Polymeric Biomaterials Biomaterial in Global Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 21 Ceramic Biomaterials Biomaterial in Global Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 22 Global Neuromodulation Devices Market Y-o-Y Growth, By End-User, 2022-2030 (%)
Figure 23 Hospitals End-User in Global Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 24 Ambulatory Surgical Centers End-User in Global Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 25 Specialized Clinics End-User in Global Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 26 Others End-User in Global Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 27 Global Neuromodulation Devices Market Y-o-Y Growth, By Region, 2022-2030 (%)
Figure 28 North America Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 29 Asia-Pacific Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 30 Europe Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 31 South America Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 32 Middle East and Africa Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 33 North America Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 34 North America Neuromodulation Devices Market Share, By Type, 2022 & 2030 (%)
Figure 35 North America Neuromodulation Devices Market Share, By Application, 2022 & 2030 (%)
Figure 36 North America Neuromodulation Devices Market Share, By Biomaterial, 2022 & 2030 (%)
Figure 37 North America Neuromodulation Devices Market Share, By End-User, 2022 & 2030 (%)
Figure 38 North America Neuromodulation Devices Market Share, By Country, 2022 & 2030 (%)
Figure 39 South America Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 40 South America Neuromodulation Devices Market Share, By Type, 2022 & 2030 (%)
Figure 41 South America Neuromodulation Devices Market Share, By Application, 2022 & 2030 (%)
Figure 42 South America Neuromodulation Devices Market Share, By Biomaterial, 2022 & 2030 (%)
Figure 43 South America Neuromodulation Devices Market Share, By End-User, 2022 & 2030 (%)
Figure 44 South America Neuromodulation Devices Market Share, By Country, 2022 & 2030 (%)
Figure 45 Europe Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 46 Europe Neuromodulation Devices Market Share, By Type, 2022 & 2030 (%)
Figure 47 Europe Neuromodulation Devices Market Share, By Application, 2022 & 2030 (%)
Figure 48 Europe Neuromodulation Devices Market Share, By Biomaterial, 2022 & 2030 (%)
Figure 49 Europe Neuromodulation Devices Market Share, By End-User, 2022 & 2030 (%)
Figure 50 Europe Neuromodulation Devices Market Share, By Country, 2022 & 2030 (%)
Figure 51 Asia-Pacific Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 52 Asia-Pacific Neuromodulation Devices Market Share, By Type, 2022 & 2030 (%)
Figure 53 Asia-Pacific Neuromodulation Devices Market Share, By Application, 2022 & 2030 (%)
Figure 54 Asia-Pacific Neuromodulation Devices Market Share, By Biomaterial, 2022 & 2030 (%)
Figure 55 Asia-Pacific Neuromodulation Devices Market Share, By End-User, 2022 & 2030 (%)
Figure 56 Asia-Pacific Neuromodulation Devices Market Share, By Country, 2022 & 2030 (%)
Figure 57 Middle East & Africa Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 58 Middle East & Africa Neuromodulation Devices Market Share, By Type, 2022 & 2030 (%)
Figure 59 Middle East & Africa Neuromodulation Devices Market Share, By Application, 2022 & 2030 (%)
Figure 60 Middle East & Africa Neuromodulation Devices Market Share, By Biomaterial, 2022 & 2030 (%)
Figure 61 Middle East & Africa Neuromodulation Devices Market Share, By End-User, 2022 & 2030 (%)
Figure 62 Medtronic Plc : Financials
Figure 63 Abbott Laboratories : Financials
Figure 64 Boston Scientific Corp : Financials
Figure 65 LivaNova Plc : Financials
Figure 66 Integer Holdings Corporation: Financials
Figure 67 ElectroCore: Financials
Figure 68 Caputron: Financials
Figure 69 NeuroPce Inc: Financials
Figure 70 Nevro Corporation: Financials
Figure 71 BrainsWay: Financials
Figure 1 Global Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 2 Global Neuromodulation Devices Market Share, By Type, 2022 & 2030 (%)
Figure 3 Global Neuromodulation Devices Market Share, By Application, 2022 & 2030 (%)
Figure 4 Global Neuromodulation Devices Market Share, By Biomaterial, 2022 & 2030 (%)
Figure 5 Global Neuromodulation Devices Market Share, By End-User, 2022 & 2030 (%)
Figure 6 Global Neuromodulation Devices Market Share, By Region, 2022 & 2030 (%)
Figure 7 Global Neuromodulation Devices Market Y-o-Y Growth, By Type, 2022-2030 (%)
Figure 8 Invasive Neuromodulation Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 9 Non Invasive Neuromodulation Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 10 Global Neuromodulation Devices Market Y-o-Y Growth, By Application, 2022-2030 (%)
Figure 11 Parkinson’s Disease Application in Global Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 12 Migraine Application in Global Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 13 Epilepsy Application in Global Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 14 Pain Management Application in Global Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 15 Tremor Application in Global Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 16 Depression Application in Global Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 17 Others Application in Global Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 18 Global Neuromodulation Devices Market Y-o-Y Growth, By Biomaterial, 2022-2030 (%)
Figure 19 Metallic Biomaterials Biomaterial in Global Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 20 Polymeric Biomaterials Biomaterial in Global Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 21 Ceramic Biomaterials Biomaterial in Global Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 22 Global Neuromodulation Devices Market Y-o-Y Growth, By End-User, 2022-2030 (%)
Figure 23 Hospitals End-User in Global Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 24 Ambulatory Surgical Centers End-User in Global Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 25 Specialized Clinics End-User in Global Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 26 Others End-User in Global Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 27 Global Neuromodulation Devices Market Y-o-Y Growth, By Region, 2022-2030 (%)
Figure 28 North America Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 29 Asia-Pacific Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 30 Europe Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 31 South America Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 32 Middle East and Africa Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 33 North America Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 34 North America Neuromodulation Devices Market Share, By Type, 2022 & 2030 (%)
Figure 35 North America Neuromodulation Devices Market Share, By Application, 2022 & 2030 (%)
Figure 36 North America Neuromodulation Devices Market Share, By Biomaterial, 2022 & 2030 (%)
Figure 37 North America Neuromodulation Devices Market Share, By End-User, 2022 & 2030 (%)
Figure 38 North America Neuromodulation Devices Market Share, By Country, 2022 & 2030 (%)
Figure 39 South America Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 40 South America Neuromodulation Devices Market Share, By Type, 2022 & 2030 (%)
Figure 41 South America Neuromodulation Devices Market Share, By Application, 2022 & 2030 (%)
Figure 42 South America Neuromodulation Devices Market Share, By Biomaterial, 2022 & 2030 (%)
Figure 43 South America Neuromodulation Devices Market Share, By End-User, 2022 & 2030 (%)
Figure 44 South America Neuromodulation Devices Market Share, By Country, 2022 & 2030 (%)
Figure 45 Europe Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 46 Europe Neuromodulation Devices Market Share, By Type, 2022 & 2030 (%)
Figure 47 Europe Neuromodulation Devices Market Share, By Application, 2022 & 2030 (%)
Figure 48 Europe Neuromodulation Devices Market Share, By Biomaterial, 2022 & 2030 (%)
Figure 49 Europe Neuromodulation Devices Market Share, By End-User, 2022 & 2030 (%)
Figure 50 Europe Neuromodulation Devices Market Share, By Country, 2022 & 2030 (%)
Figure 51 Asia-Pacific Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 52 Asia-Pacific Neuromodulation Devices Market Share, By Type, 2022 & 2030 (%)
Figure 53 Asia-Pacific Neuromodulation Devices Market Share, By Application, 2022 & 2030 (%)
Figure 54 Asia-Pacific Neuromodulation Devices Market Share, By Biomaterial, 2022 & 2030 (%)
Figure 55 Asia-Pacific Neuromodulation Devices Market Share, By End-User, 2022 & 2030 (%)
Figure 56 Asia-Pacific Neuromodulation Devices Market Share, By Country, 2022 & 2030 (%)
Figure 57 Middle East & Africa Neuromodulation Devices Market Value, 2021-2030 (US$ Billion)
Figure 58 Middle East & Africa Neuromodulation Devices Market Share, By Type, 2022 & 2030 (%)
Figure 59 Middle East & Africa Neuromodulation Devices Market Share, By Application, 2022 & 2030 (%)
Figure 60 Middle East & Africa Neuromodulation Devices Market Share, By Biomaterial, 2022 & 2030 (%)
Figure 61 Middle East & Africa Neuromodulation Devices Market Share, By End-User, 2022 & 2030 (%)
Figure 62 Medtronic Plc : Financials
Figure 63 Abbott Laboratories : Financials
Figure 64 Boston Scientific Corp : Financials
Figure 65 LivaNova Plc : Financials
Figure 66 Integer Holdings Corporation: Financials
Figure 67 ElectroCore: Financials
Figure 68 Caputron: Financials
Figure 69 NeuroPce Inc: Financials
Figure 70 Nevro Corporation: Financials
Figure 71 BrainsWay: Financials
